Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | See Remarks | July 01, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date July 01, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 232,693 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 14,858 · Balance 232,693 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IRONWOOD PHARMACEUTICALS INC
Report date February 26, 2021 · Filed March 02, 2021
Section 16 reporting ended · disclosed 2021-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 127,926 |
Reported balance
After 2021-02-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-26 · Sale · Disposed 1,399 · Balance 127,926 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2: The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020. |
| Class A Common StockSEC Table I · non-derivative | Direct | 126,452 |
Reported balance
After 2021-02-26 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-02-26 · Sale · Disposed 1,474 · Balance 126,452 F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018. |
| Class A Common StockSEC Table I · non-derivative | Direct | 124,184 |
Reported balance
After 2021-02-26 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-02-26 · Sale · Disposed 2,268 · Balance 124,184 F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. |
| Class A Common StockSEC Table I · non-derivative | Direct | 122,336 |
Reported balance
After 2021-02-26 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2021-02-26 · Sale · Disposed 1,848 · Balance 122,336 F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
F2: The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020.
F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018.
F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 1, 2026 20:35 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 14,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-292685 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,693 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 16, 2026 22:49 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 11,738 | $7.02 | $82,400.76 |
DisclosureSEC source: 0001193125-26-159579 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,835 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 112,661 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-088170 · ownership.xml · derivative · entry 2 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,661 Underlying: Common Stock · 112,661 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 62,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088170 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,573 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:48 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 12,079 | $5.05 | $60,998.95 |
DisclosureSEC source: 0001193125-26-055499 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,234 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 00:36 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 7,162 | $5.49 | $39,319.38 |
DisclosureSEC source: 0000950170-25-054953 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,313 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.48 to $5.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 59,525 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0000950170-25-013827 · ownership.xml · derivative · entry 2 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,525 Underlying: Common Stock · 59,525 shares Expires 2035-02-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 90,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013827 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,475 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0000950170-24-041803 · ownership.xml · derivative · entry 2 Kilroy Conor · CIK 0001808510 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2034-04-01 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on April 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041803 · ownership.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2025, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,848 | $9.11 | $16,835.28 |
DisclosureSEC source: 0001209191-21-016029 · doc4.xml · nonDerivative · entry 4 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,336 F5 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,268 | $9.11 | $20,661.48 |
DisclosureSEC source: 0001209191-21-016029 · doc4.xml · nonDerivative · entry 3 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,184 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,474 | $9.11 | $13,428.14 |
DisclosureSEC source: 0001209191-21-016029 · doc4.xml · nonDerivative · entry 2 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,452 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,399 | $9.11 | $12,744.89 |
DisclosureSEC source: 0001209191-21-016029 · doc4.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,926 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · balance_after: The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 237 | $10.92 | $2,588.04 |
DisclosureSEC source: 0001209191-20-057608 · doc4.xml · nonDerivative · entry 2 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,833 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 15, 2017. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 599 | $10.92 | $6,541.08 |
DisclosureSEC source: 0001209191-20-057608 · doc4.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,070 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16, 2016. F2 · balance_after: The reporting person acquired 748 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| May 11, 2020 Filed May 13, 2020 21:19 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 558 | $10.35 | $5,775.30 |
DisclosureSEC source: 0001209191-20-028895 · doc4.xml · nonDerivative · entry 2 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,921 F2 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
| May 11, 2020 Filed May 13, 2020 21:19 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 158 | $10.35 | $1,635.30 |
DisclosureSEC source: 0001209191-20-028895 · doc4.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,479 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on August 1, 2016. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025917 · doc4.xml · nonDerivative · entry 1 Kilroy Conor · CIK 0001808510 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,637 F1 · kind: The restricted stock units, granted as a promotion award, vest as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.